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Abstract
Background: Genomic sequencing in cancer (both tumour and germline), and development of therapies targeted to
tumour genetic status, hold great promise for improvement of patient outcomes. However, the imminent introduction
of genomics into clinical practice calls for better understanding of how patients value, experience, and cope with this
novel technology and its often complex results. Here we describe a protocol for a novel mixed-methods, prospective
study (PiGeOn) that aims to examine patients’ psychosocial, cognitive, affective and behavioural responses to tumour
genomic profiling and to integrate a parallel critical ethical analysis of returning results.
Methods: This is a cohort sub-study of a parent tumour genomic profiling programme enrolling patients with advanced
cancer. One thousand patients will be recruited for the parent study in Sydney, Australia from 2016 to 2019. They will be
asked to complete surveys at baseline, three, and five months. Primary outcomes are: knowledge, preferences, attitudes
and values. A purposively sampled subset of patients will be asked to participate in three semi-structured interviews (at
each time point) to provide deeper data interpretation. Relevant ethical themes will be critically analysed to iteratively
develop or refine normative ethical concepts or frameworks currently used in the return of genetic information.
Discussion: This will be the first Australian study to collect longitudinal data on cancer patients’ experience of tumour
genomic profiling. Findings will be used to inform ongoing ethical debates on issues such as how to effectively obtain
informed consent for genomic profiling return results, distinguish between research and clinical practice and manage
patient expectations. The combination of quantitative and qualitative methods will provide comprehensive and critical
data on how patients cope with ‘actionable’ and ‘non-actionable’ results. This information is needed to ensure that when
tumour genomic profiling becomes part of routine clinical care, ethical considerations are embedded, and patients are
adequately prepared and supported during and after receiving results.
Trial registration: Not required for this sub-study, parent trial registration ACTRN12616000908437.
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Background
Despite treatment advances in recent years, survival
rates in some cancers have only minimally improved. [1]
As such, there is a significant need for new approaches
to increase patient survival and reduce morbidity.
Tumour genomic profiling (TGP) and personalized
treatment offer new opportunities for improvement in
cancer outcomes. It is anticipated that TGP will increas-
ingly allow identification of cancer patients who will
benefit from targeted drugs and immunotherapy ap-
proaches, in contrast to current ‘scatter-gun’ approaches
of chemotherapy and radiotherapy. [2]
There are generally two types of genomic sequencing in
the cancer context: TGP and germline genomic sequencing
(GGS). TGP involves laboratory analysis of somatic tissue
to identify somatic driver mutations in tumours, whereas
GGS involves examination of the entire genome through a
blood sample seeking germline variants associated with
cancer predisposition syndromes. This study focuses on
TGP. A second study examining the psychosocial, behav-
ioural and ethical issues and outcomes of GGS on cancer
probands and their blood relatives is also underway and its
protocol will be published separately. The two sub-studies
together represent The P (psychosocial) i(n) Ge (genomics)
On (oncology) PiGeOn project.
TGP involves panel or whole genome testing of DNA
derived from tumours. This may identify gene variants
that can inform choice of treatments targeting the
specific gene variants present in the tumour. TGP can
identify somatic variants that: i) affect treatment (clinic-
ally actionable); ii) do not affect treatment (non-action-
able); or iii) are of uncertain significance. TGP can be
followed by further confirmatory testing if it is suspected
that gene variants may have a germline origin (and
therefore may also be relevant to the patient’s family).
The promise of genomic medicine will only be realised
if patients understand and benefit from identification of
gene variants; that is, they need to understand the
chances of finding actionable variants, and any potential
implications of results. While uncertainty in terms of
potential information available pervades TGP less than
GGS due to the smaller scope of testing, there remains
an element of uncertainty due to the poor prognosis of
most patients and the uncertainty of the results being
clinically actionable, and also the chance of finding a
germline variant with the subsequent implications of
testing for the recipient’s blood relatives. Practitioners
who obtain consent for TGP face the challenges of con-
veying these uncertainties to both ensure informed
choice regarding testing and to mitigate any unrealistic
expectations.
Further, although uncertainty may be shared among
stakeholders, such as during education sessions between
physician and patient, the extent of intricacy within
genomic testing can lead to both parties remaining un-
aware of their areas of ignorance. [3] The expected fu-
ture expansion of TGP to other healthcare providers and
non-genetics specialists raises questions of 1) how best
to approach the consent process, and 2) about disclosure
of complex results when providers may have limited
training and/or expertise in genetics. While patient au-
tonomy, informed consent and shared decision-making
are established standards in health care, there are no
guidelines on how patients should be engaged with re-
gard to the decision to have TGP, nor how uncertainty
should be approached in this complex area. Debate is
ongoing. [4]
We have little understanding of the ethical, psycho-
social and behavioural implications of providing cancer
patients with results from TGP, and whether it will be
experienced differently to other medical tests. The
published evidence has been gathered primarily from re-
search participants who may or may not have cancer,
where the potential benefits of a gene variant being
present (such as access to novel therapeutic options)
differ. Several North American studies [5–7] presenting
hypothetical scenarios to cancer patients regarding
TGP, found the majority would be interested in
tumour profiling, although the participants felt they
had insufficient knowledge to make an informed
choice. While a majority of patients in hypothetical
scenarios expressed a willingness to undergo TGP for
personalized treatment, many also expressed signifi-
cant concerns about potential psychological harm,
cost and discrimination. Misunderstandings about
TPG were also noted. [5]
Overall, very little is known about the knowledge,
preferences, attitudes and values of cancer patients who
have actually undergone TGP, their experience of uncer-
tainty, their behaviour on receipt of TGP results, or the
psychological effects these results may have. Only a
handful of studies have explored responses in cancer
patients who have actually been offered TGP. These
have primarily noted patient report of information
overload and misunderstanding, leading to unrealistic
expectations, anxiety and uncertainty [8–10]. Patient
hopes of benefit from TPG were enhanced by the prom-
ise of novel and targeted treatment but challenged by
non-findings or by limited access to relevant trials. [8]
To our knowledge, none of the studies of patients who
have actually undergone TGP testing have reported
longitudinal data.
Oncologists were among the first clinicians to incorpor-
ate TGP into routine management to guide treatment
choice. Unifocal profiling goes back to estrogen receptor
status testing in breast cancer and then EGFR mutation in
lung cancer, with recent testing of the KRAS gene in colo-
rectal cancer and the BRAF gene in melanoma. [11, 12] It
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is critical to explore how patients value and experience
TGP, and cope with uncertainty, non-actionable results
and incidental findings, as well as informative findings, as
TGP increasingly enters routine oncological clinical
practice.
This paper outlines the protocol of the first Australian
study collecting longitudinal data on cancer patients’
experiences of TGP over time.
Guiding theory
The design and measures for the study are guided by
Protection Motivation Theory [13] and Differentiation
and Consolidation Theory. [14] Protection Motivation
Theory proposes that we protect ourselves based on
the perceived severity and probability (vulnerability)
of a threat, perceived efficacy of preventive behaviour,
and perceived self-efficacy in performing the prevent-
ive behaviour. Differentiation and Consolidation the-
ory states that decision-making reflects a process of
gradual differentiation including: identifying options
with perceived important attributes, prioritising one
or two options based on highly ranked attributes and
reconsidering an initial preference based on further
information. This is followed by a consolidating
process, which focuses on one’s values, and future
possible outcomes, to favourably reinforce the chosen
option and thereby prepare for potential threats, re-
gret and doubt.
In this setting, protection motivation will be the
result of perceived susceptibility to disease progres-
sion and death, and fear of cancer progression, as
well as participant knowledge of, attitudes to, and
value given to, TGP (as a strategy to guide more
effective treatment and thus reduce the threat of
disease progression). Patients who perceive TGP to
be valuable will be more likely to remain satisfied
with their decision to undertake TGP, regardless of
results, and to act on positive results by joining
appropriate clinical trials of tailored treatments.
Intolerance of uncertainty may make TGP less at-
tractive and increase the likelihood of regret, doubt
and poor psychological outcomes.
Methods/design
Aims and hypotheses
The aim of this study in adults with advanced cancer
undergoing TGP is to:
1) Before and after receipt of results: evaluate
knowledge of TGP, preferences for genetic
information, attitudes (positive and negative) and
the value placed on TGP;
2) After receipt of results: identify behavioural,
decisional and psychological outcomes from TGP
along with their respective predictors; and
3) Contextualize the findings via a critical bioethics
analysis.
Specific hypotheses are that:
1. At baseline (after giving informed consent to
undergo TGP), advanced cancer patients will have
moderate to poor knowledge about TGP (< 55%
correct on knowledge scale).
2. At baseline, advanced cancer patients will have
primarily positive attitudes to, and highly value,
TGP.
3. Of advanced cancer patients who receive an
actionable result, most will:
a). Pursue personalised treatment in a clinical trial
setting (behavioural outcomes).
b). Cope well with results, and experience low
decisional conflict and regret and high
decisional satisfaction (decisional outcomes).
c). Have higher hope, less cancer-related anxiety,
lower fear of cancer progression and lower gen-
eral anxiety and depression than those who do
not receive actionable results (psychosocial
outcomes).
4. Those advanced cancer patients who have no
actionable variants identified will:
a). Struggle to cope with non-results (decisional
outcomes).
b). Have levels of hope, cancer-related anxiety, fear of
cancer progression and general anxiety and depres-
sion similar to published results for advanced can-
cer patients who have not undergone TGP, within
1 month of receiving results and 5 months later
(psychosocial outcomes).
5. Predictors of behavioural, decisional and
psychological outcomes within 1 month of receiving
results and 5 months later, will include:
a). Age, education level, ethnicity, and gender;
b). Tolerance of uncertainty and baseline
knowledge; and
c). Preferences and attitudes to TGP.
Methodology in critical bioethics analysis is not
hypothesis-driven and to this end there are no hypoth-
eses relating to this part of the analysis.
Parent study
The Genomic Cancer Medicine Program includes a
large cohort study funded by the NSW Ministry of
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Health, Australia, the Molecular Screening and Thera-
peutics (MoST) Program. MoST is recruiting 1000
adult patients with pathologically confirmed advanced
or metastatic solid cancer with a particular focus on
rare or neglected cancers. Participants undergo TGP,
and receive results at approximately 11 weeks. Their
treating oncologist is informed of results and dis-
cusses results and treatment options with the patient.
Possible treatment options identified through TGP in-
clude a clinical trial offered as part of the MoST pro-
gram, another clinical trial available in Australia, or
off-label treatment through the treating clinician. This
cohort offers the opportunity to explore short- and
long-term impacts on behaviour and psychological
morbidity of receiving TGP results. The PiGeOn pro-
ject constitutes a psycho-social/ethical sub-study in
this cohort, employing mixed methods to gather
patient-reported outcomes and qualitative data.
Research design
This is a mixed method, prospective, cohort sub-study
of a TGP programme enrolling patients with advanced
cancer.
Setting
Participants will be recruited by the parent programme,
from incident and prevalent cases at three large tertiary
oncology units in Sydney hospitals. All suitable partici-
pants will provide informed consent using established
procedures for genetic research, validated by large ge-
netic studies. [13, 14] The scope of this consent includes
TGP as well as completion of questionnaires and inter-
views. Participants are provided with actionable and
non-actionable results from TGP and they can elect
whether they want germline genetic results confirmed
by Sanger sequencing and returned. Patients for whom
germline variants are found will have their decision to
be informed confirmed, then directed to a genetic
counsellor for further information.
Participants
The target population includes patients with pathologic-
ally confirmed advanced or metastatic solid cancer of
any histologic type. Patients with rare or neglected can-
cers (defined as an incidence of less than 6/100,000 of
the general population and cancers of unknown primary
site) will be given priority.
Inclusion criteria include: age 18 years or older;
pathologically confirmed advanced and/or metastatic
solid cancer or an earlier diagnosis of a poor progno-
sis cancer; sufficient and accessible tissue for TGP;
failed all standard anticancer therapy or receiving last
line of standard therapy at time or enrolment; Eastern
Cooperative Oncology Group Performance Status
Measure (ECOG) performance status 0, 1 or 2; willing
and able to comply with all study requirements, in-
cluding timing and/or nature of required assessments;
and written informed consent.
Exclusion criteria include: suitability for standard
therapy, if the patient has not been previously treated;
specific co-morbidities or conditions which may
contraindicate participation or compromise assess-
ment of key outcomes; history of another malignancy
within 2 years prior to registration: pregnancy, lacta-
tion or inadequate contraception.
Procedure for PiGeOn
Patients will provide consent to MoST staff for the
psychosocial (PiGeOn) sub-study at the same time as
they give consent to the parent TPG program. Thus
at baseline they will have already considered and
given consent to TGP, but not yet had TGP. Partici-
pants will be asked to complete a questionnaire (hard
copy, online or via telephone if they prefer) at base-
line (T0), 1 to 4 weeks after receiving TGP results
(T1, approximately 2–3 months post baseline), and at
2 months (T2) after T1. These timeframes have been
chosen to allow impacts of the test results to be
captured in both the short-term (when a treatment
decision is being made) and longer-term (while
undergoing or near to completion of targeted therapy,
if adopted). A small subset (around 20–40 partici-
pants) will be invited to participate in semi-structured
interviews at the same assessment time points to ex-
plore in more detail attitudes towards TPG and its
associated psycho-social, behavioural and ethical
aspects. See Fig. 1.
Measures
The following patient-reported measures will be col-
lected (see Table 1).
Demographic data
Age, gender, marital status, education level, occupa-
tion, language spoken at home and history of genetic
screening collected by patient report at baseline.
Sociodemographic status will be derived from
National Census data based on location of residence.
Disease details
Available from the MoST database, including family his-
tory, primary site, detailed staging, ECOG performance
status, treatment and co-morbidities.
The following validated (some adapted) outcome mea-
sures will be administered at baseline only:
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Perceived importance of TGP
This 2-item measure adapted from Hay et al. [15]
assesses perceived importance of genetic information
to the participant, using a Likert scale. Specifically,
the questions pertain to importance of learning about
how genes affect the chance of responding to particu-
lar cancer treatment, and how lifestyle affects the
chance of living longer with cancer. High scores indi-
cate greater importance.
Knowledge
A 9-item, multiple choice, study-developed question-
naire assessing knowledge of the purpose of TGP, likely
frequency of informative results, cancers in which in-
formative results are more likely to be found, availability
of tailored treatment options, and source of genetic
knowledge. Scores are summed, with high scores indicat-
ing greater knowledge.
Self-efficacy
Four items adapted from Rosenberg et al., [16] assessing
perceived ability to cope if actionable, non-actionable, or
germline results are found. High scores indicate greater
perceived ability to cope.
Value of TGP
A hypothetical time trade-off scenario based on those used
in three previous studies. [17–19] Six items assess how the
likelihood of finding an informative result impacts willing-
ness to have TGP, and the amount the participant would be
willing pay for TGP (from $0 to $10,000) if TGP found an
informative result in 1, 20, or 40 people out of 100.
Preferences for being informed of results
Four Likert-scale items adapted from Tabor et al., [20]
assessing desire for results informing: treatment, prognosis,
and family risk of cancer (yes / no / maybe / don’t know).
Coping with uncertainty
Eight Likert-scale items from Kasparian et al., [21] mea-
suring reaction to uncertainty, ambiguity and the future.
High scores indicate greater intolerance.
Fig. 1 Assessment schedule. MoST PS: MoST Psychosocial (PiGeOn) sub-study
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Note that to reduce participant burden at baseline,
measures of psychological morbidity (anxiety, depres-
sion, hope) were not included at T0.
The following outcome measures will be administered
at the first follow-up only:
Coping with genetic test results
The 25-item Multidimensional Impact of Cancer Risk As-
sessment [22] assessing impact of result disclosure after
genetic testing. High scores indicate greater distress.
Decisional conflict regarding tailored treatment
Ten items from the Decisional Conflict Scale [23] com-
prises 5 subscales measuring: 1) uncertainty, 2) feelings of
being uninformed, 3) clarity of values, 4) sense of being un-
supported in decision-making, and 5) evaluation of the
quality of the decision. High scores indicate lower deci-
sional conflict.
The following outcome measures will be administered
at the first and second follow-ups:
Cancer-related anxiety
The 15-item Impact of Events Scale [24] assesses
cancer-related anxiety, in two subscales, intrusive think-
ing and avoidance. High scores indicate greater cancer-
related anxiety.
Anxiety and depression
The 14-item Hospital Anxiety and Depression Scale [25]
comprises two 7-item sub-scales measuring anxiety and
depression. High scores indicate greater morbidity.
Table 1 Survey measures
Domain Measures Baseline
(T0)
Follow-up 1 (T1) (within 4 weeks
of return of results, ~ 2–3 months)
Follow-up 2 (T2)
(2 months post T1)
Demographics
Age, gender, marital status,
education level, occupation etc
Demographic items X
Views and attitudes





Adapted from Jamal et al. [18] X X
Result return preferences Adapted from Tabor et al. [19] X
Knowledge Study-developed X
Perceived importance of TGP Adapted from Hay et al. [20] X
Psychological predictors
Coping with uncertainty Kasparian et al. [21] X
Self-efficacy Adapted from Rosenberg
et al. [22]
X
Perceived susceptibility Adapted from
Kasparian et al. [21]
X X X
Psychological outcomes
Coping with TGP results Multidimensional impact of
cancer risk assessment [23]
X
Fear of cancer progression Concerns about Recurrence Questionnaire [24] X X X
Cancer -specific anxiety Impact of events scale [25] X X
Anxiety and depression Hospital anxiety and depression
scale [26]
X X
Hope Herth Hope Index [27] X X
Decisional outcomes
Decisional conflict Decisional conflict scale [28] X
Decisional regret regarding
personalised treatment
Decision regret scale [29] X
Decisional satisfaction Satisfaction with Decision
Scale [30]
X X
TGP, Tumour genomic profiling
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Hope
The 12-item Herth Hope Index [26] measures hope and
sense of meaning, with 3 subscales: temporality and
future, positive readiness and expectancy, and inter-
connectedness. High scores indicate greater hope.
The following outcome measure will be administered
at the second follow-up:
Decisional regret
The 5-item Decisional Regret Scale [27] measures health
care decision regret about the decision to have TGP.
High scores indicate greater regret.
The following outcome measures will be administered
at baseline and first follow-up:
Perceived benefits and drawbacks of TGP
Two open ended questions adapted from an earlier
study [28] assessing perceived specific benefits and
drawbacks of TGP.
Satisfaction with decision to have TGP
The 6-item Satisfaction with Decision scale [29] mea-
sures satisfaction with decision to have TGP. Items are
rated on a Likert scale. High scores indicate greater
satisfaction.
The following outcome measures will be administered
at baseline and all follow-ups:
Fear of cancer progression
Three items from the Concerns about Recurrence
Questionnaire [30], adapted to measure fear of cancer
progression. High scores indicate greater fear.
Perceived susceptibility
Participants indicate perceived likelihood of having a
gene fault that increases risk of cancer progression on a
visual analogue scale (0–100%) adapted from Kasparian
et al. [21]
Qualitative interviews
A subset of participants will be invited to participate in
three semi-structured interviews (at baseline and each
follow-up). Recruitment will continue until saturation is
reached. [31] As the majority of this sample population
is expected to have non-actionable results, additional
participants, purposively sampled to include those who
have received actionable or incidental findings, will be
recruited at follow-up 1 and re-interviewed at follow-up
2. Similarly, purposive sampling will be used to ensure
that both patients who elect to receive, and not receive,
germline results (if available) will be included. Also, the
opportunity to contrast TGP with the experience of
having previously undergone testing for a single variant
to personalize treatment will be taken where possible.
Interviews will explore views on who should be offered
TGP, attitudes to disclosure of results, perceived benefits
and challenges of TGP, ethical aspects of TPG testing
and experiences of receiving informative and uninforma-
tive results.
Sample size
The MoST study plans to recruit 1000 patients over
three years. Thus, with a conservative retention and
survival estimate of 75%, this is reduced to at fewest 469
patients. With this sample size estimate, assuming 15%
of patients receive an actionable result and using a sig-
nificance level of 0.05, this project: has 90% power to de-
tect a mean change of 5.8 and 2.6 points on the Impact
of Events scale for patients with actionable and non-
actionable results respectively (paired t-test, SD = 15)
[32] and a mean difference of 4.5 points between
patients with actionable and non-actionable results;
Multiple regression with at most 24 explanatory vari-
ables (including dummy variables) has 90% power to de-
tect significant categorical variables with 5 categories
(largest possible categorical variable) when that predictor
explains greater than 3.6% of the residual variance, or to
detect a continuous variable when it explains more than
2.3% of the residual variance. For patients with action-
able results only (at fewest 70), at 80% power the mini-
mum variance explained for continuous variables would
be 12% of the residual variance, and 15% for binary pre-
dictors. For logistic regression when outcomes are on
average equally likely the power to detect an odds ratio
of 1.4 is 95% or 80% when the other covariates explain
zero, or 37% of the outcome variance respectively. For
only those with actionable results, there is 80% power to
detect an odds ratio of 2.14 or greater if the other
outcomes explain zero outcome variance.
Qualitative data analysis
Interviews will be recorded and transcribed verbatim
and manually coded line-by-line. Transcripts will be sub-
jected to Framework Analysis, [33] allowing compari-
sons within and between transcripts. QSR N-Vivo 11
will be used to manage the dataset. A multi-disciplinary
team will be involved in analysis to ensure reflexivity.
The resulting data will be cross-referenced with quanti-
tative data to provide greater richness to the data-set.
This data will also be critically interrogated as part of
the ethical analysis. [34]
Ethical analysis
Ethical concepts and analysis will be relevant throughout
this project, and will be iteratively and critically reflected
upon as the study progresses. Quantitative survey items
allowing free-text responses regarding benefits and
drawbacks of TGP will allow the study team to see
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whether any responses assist in identifying relevant ethical
themes; such as how participants view autonomous
decision-making or cost considerations. Data from quali-
tative interviews will be critically compared with bioethics
literature regarding concepts such as family communica-
tion, duties to disclose, what constitutes autonomous
decision-making, approaching uncertainty in TGP, the dis-
tinction between research and clinical practice, obligations
at the conclusion of a research project and determining
when it is appropriate to offer testing; and to whom. The
result will be a series of normative positions, defensible
using ethical reasoning and informed by empirical data.
Quantitative data analysis
Mean differences in outcomes will be compared using
t-test (continuous) or chi-squared tests (dichotomous).
Non-parametric tests will also be used where appro-
priate. Temporal changes in scales will be investigated
by calculating the difference between time-points.
Multiple (continuous outcomes) or logistic (dichotom-
ous outcomes) regression will be used to adjust for
the effect of confounders and identify predictors of
outcome. Linear mixed models and logistic mixed
models will be carried out in R: A language and
environment for statistical computing using package
nlme for the linear mixed model and lme4 for the
logistic mixed model. Assumptions of normality of re-
siduals and homogeneity of variance will be checked
visually though diagnostic residual plots. Multivariable
models will be constructed with the inclusion of all
potential confounders, and those predictors that show
weak evidence for an association with the outcome in
univariate analysis. Backwards elimination followed by
forwards addition will be used to select predicting
variables in the final model. Known and identified
confounders will be included regardless of their statis-
tical significance. Collinear independent variables will
be identified and removed.
Discussion
The PiGeOn study advances the field by identifying the
knowledge, values, attitudes and coping strategies of
patients with regards to TGP, determining how these,
and other factors, predict subsequent cancer-related be-
haviour and psychosocial outcomes, and aligning these
with current ethical norms. It will be the first Australian
study to collect longitudinal data on cancer patients’
experience of TGP over time.
The trial experience of the first 100 patients
revealed the unexpected finding that a significant
proportion of the cohort was eligible for both this
sub-study, and the twin psychosocial sub-study, which
involved participants undergoing GGS. This group
will be treated as a separate cohort, as they will be
facing the combined challenges of uncertainty related
to prognosis/treatment related outcomes of the MoST
component, as well as the germline implications for
identifying increased cancer risk for blood relatives.
Previous research using hypothetical scenarios unsur-
prisingly suggests that patients with cancer have
greater concerns about GGS than TGP. [5] This study
will provide the opportunity to explore attitudes of
patients who have elected to undergo both.
Methodological issues considered in the develop-
ment of this study included the timing of the
psychosocial assessments, including questionnaires.
Timing was crucial in order to capture participant
experiences and this was modified early based on
data collected in the initial phase of the programme.
Given it is expected that 5–10% of the cohort will
have actionable somatic mutations, sampling for the
qualitative component will be manipulated between
baseline and follow-up 1 to allow for exploration of
the reaction to both return and non-return of
actionable results. The follow-up 1 cohort will be
reassessed qualitatively at the subsequent follow-ups.
It is recognized that there may be challenges in
maintaining the follow-up of patients not receiving
actionable results, although cancer populations are
known to be highly motivated to contribute to
research. [35] It will be important to capture the ex-
perience of having hopes of finding a novel cure
raised in 100% of poor prognosis patients only to
have them dashed in the at least 90% in whom noth-
ing is found. [36]
Given the information needs and preferences are
expected to vary, the qualitative and ethical compo-
nents have been included to capture and critically re-
flect on the complexity of and nuances within patient
expectations, their understanding of the implications
of TGP, the likelihood of receiving an actionable som-
atic result and their attitudes towards sharing results
with potential familial repercussions even if they did
not receive such a result. Qualitative research has
value in understanding these processes. [37]
Genomic sequencing (tumour and germline) is
likely to become pervasive across healthcare, and to
influence cancer diagnosis, treatment and prognosti-
cation. It gives rise to testing methods that are both
diagnostic and predictive on a scale not previously
seen in healthcare. The PiGeOn study results will in-
form ongoing ethical debate on issues relevant to
the large-scale introduction of genomic testing into
the clinical space, such as guidelines for truly
obtaining informed consent for genomic testing as
well as assenting to unknown future research. In
addition, although somatic testing rarely identifies
germline mutations, relevant to family members, it
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has already been reported in our study and others.
[38] The PiGeOn Project will also provide critical
outcome data concerning the psychosocial impact of
receiving genomic results on patients. These data are
needed to ensure that when genomic testing is intro-
duced into routine clinical care, ethical concepts are
well embedded, and patients are adequately prepared
and supported during and after the testing process.
Given the dearth of information on participant
responses to actual TGP for cancer, this study is an
important step in filling the gap in knowledge about
how best to introduce this form of genomic testing
into clinical practice.
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